Arcutis Biotherapeutics (ARQT) Expected to Announce Quarterly Earnings on Tuesday

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) is projected to post its earnings results before the market opens on Tuesday, February 25th. Analysts expect Arcutis Biotherapeutics to post earnings of ($0.28) per share and revenue of $60.52 million for the quarter. Parties interested in participating in the company's conference call can do so using this link.

Arcutis Biotherapeutics Stock Down 2.3 %

Arcutis Biotherapeutics stock traded down $0.31 on Friday, hitting $13.11. 617,043 shares of the stock traded hands, compared to its average volume of 2,105,950. The business's fifty day simple moving average is $13.66 and its 200 day simple moving average is $11.30. The firm has a market cap of $1.53 billion, a P/E ratio of -7.33 and a beta of 1.29. The company has a current ratio of 2.46, a quick ratio of 2.38 and a debt-to-equity ratio of 0.67. Arcutis Biotherapeutics has a 1 year low of $6.99 and a 1 year high of $16.20.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ARQT. HC Wainwright reaffirmed a "buy" rating and issued a $19.00 price target on shares of Arcutis Biotherapeutics in a research report on Monday, January 13th. Guggenheim reiterated a "buy" rating on shares of Arcutis Biotherapeutics in a research note on Monday, February 10th. Needham & Company LLC reissued a "buy" rating and set a $18.00 price target on shares of Arcutis Biotherapeutics in a research report on Thursday, November 7th. Finally, Mizuho upped their price objective on Arcutis Biotherapeutics from $19.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.60.

Insider Transactions at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, insider Masaru Matsuda sold 8,338 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $12.70, for a total value of $105,892.60. Following the transaction, the insider now directly owns 178,692 shares of the company's stock, valued at approximately $2,269,388.40. This trade represents a 4.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Todd Franklin Watanabe sold 15,000 shares of the business's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $15.17, for a total value of $227,550.00. Following the sale, the insider now owns 823,430 shares of the company's stock, valued at approximately $12,491,433.10. This represents a 1.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 55,029 shares of company stock worth $756,017 in the last ninety days. Insiders own 9.50% of the company's stock.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.